Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Lee's Pharm Affiliate Conducting China Phase III Trial of Combo Treatment for Severe Acne

publication date: Nov 25, 2019

China Ophthalmology Focus Limited (COPFL) of Guangzhou completed enrollment of its large Phase III trial of an Adapalene-Clindamycin Combination Gel in China in patients with severe acne vulgaris. COPFL is a non-wholly owned subsidiary of Lee's Pharm that raised $50 million in a Series A round earlier this year. Through its subsidiary, Zhaoke, COFPL owns a development and production facility in Guangzhou that is developing a portfolio over 21 ophthalmology proprietary products and difficult-to-manufacture generics for China and ASEAN markets. The facility is compliant with all international standards. More details....

Stock Symbol: (HK: 0950)]

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.